{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:13:51Z","timestamp":1793067231892,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Functional Gastrointestinal disorders (FGIDs) are highly prevalent among adolescents. Increased intestinal permeability plays a potential role in the pathogenesis of FGIDs. Claudin-3 (CLDN3) may serve as an indicator of gut barrier integrity. We aimed to assess serum level of CLDN3 as a noninvasive biomarker of intestinal permeability in adolescents with FGIDs, and its relation with inflammatory markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 70 adolescents with FGIDs and 65 healthy controls. Serum levels of CLDN3 and inflammatory markers; C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF\u03b1), and haptoglobin, were measured using enzyme-linked immunosorbent assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum levels of CLDN3 and inflammatory markers; CRP, Il-6, TNF\u03b1 and haptoglobin, were significantly higher in cases compared to controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02, 0.039, 0.04, 0.021 and 0.001, respectively). We detected significant positive correlations between serum level of CLDN3 and that of CRP, IL-6 and haptoglobin in cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results revealed significant elevations in serum levels of CLDN3 and inflammatory markers in adolescents with FGIDs. Significant positive correlations were detected between levels of CLDN3 and that of CRP, IL-6 and haptoglobin, suggesting an association between intestinal barrier dysfunction and low-grade systemic inflammation. Thus, CLDN3 represents a potential noninvasive biomarker of intestinal permeability in FGIDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This research investigated the potential role of Claudin-3 (CLDN3) as a noninvasive biomarker of intestinal permeability in adolescents with Functional Gastrointestinal Disorders (FGIDs), and its relation to the inflammatory status of these patients.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>To the best of our knowledge, this is the first study to assess serum CLDN3 as a noninvasive biomarker of intestinal permeability in FGIDs; previous researches have assessed intestinal barrier disruption in FGIDs based on intestinal biopsies.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Our findings suggest that impaired intestinal barrier function may promote development of FGIDs by inducing inflammation. Thus, restoration of intestinal barrier integrity may represent a potential therapeutic target for FGIDs.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-026-05497-0","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:51:34Z","timestamp":1791222694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2521-7076","authenticated-orcid":false,"given":"Azza","family":"Abd El-Shaheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-218X","authenticated-orcid":false,"given":"Nermine N.","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4555-3760","authenticated-orcid":false,"given":"Heba H.","family":"Metwaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0414-0567","authenticated-orcid":false,"given":"Hiba","family":"Sibaii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-5803","authenticated-orcid":false,"given":"Safa N.","family":"Abd El-Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"5497_CR1","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3390\/nu14081578","volume":"14","author":"V Giorgio","year":"2022","unstructured":"Giorgio, V. et al. Intestinal permeability in children with functional gastrointestinal disorders: the effects of diet. Nutrients 14, 1578, https:\/\/doi.org\/10.3390\/nu14081578 (2022).","journal-title":"Nutrients"},{"key":"5497_CR2","doi-asserted-by":"publisher","first-page":"101698","DOI":"10.1016\/j.cegh.2024.101698","volume":"28","author":"D Jabeen","year":"2024","unstructured":"Jabeen, D., Verma, S. & Bhatnagar, S. A prevalence study of functional gastrointestinal disorders among the school-going adolescent population in an urban city in northern India. Clin. Epidemiol. Glob. Health 28, 101698, https:\/\/doi.org\/10.1016\/j.cegh.2024.101698 (2024).","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"5497_CR3","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.pain.2012.03.026","volume":"153","author":"LS Walker","year":"2012","unstructured":"Walker, L. S., Sherman, A. L., Bruehl, S., Garber, J. & Smith, C. A. Functional abdominal pain patient subtypes in childhood predict functional gastrointestinal disorders with chronic pain and psychiatric comorbidities in adolescence and adulthood. Pain 153, 1798\u20131806, https:\/\/doi.org\/10.1016\/j.pain.2012.03.026 (2012).","journal-title":"Pain"},{"key":"5497_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/diagnostics15030242","volume":"15","author":"MA Khatib","year":"2025","unstructured":"Khatib, M. A. et al. Prevalence of functional gastrointestinal disorders and associated risk factors among preschool children in the city of Jeddah and surrounding areas: a cross-sectional study. Diagnostics 15, 242, https:\/\/doi.org\/10.3390\/diagnostics15030242 (2025).","journal-title":"Diagnostics"},{"key":"5497_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/biomedicines12030702","volume":"12","author":"D \u0160ojat","year":"2024","unstructured":"\u0160ojat, D. et al. Putting functional gastrointestinal disorders within the spectrum of inflammatory disorders can improve classification and diagnostics of these disorders. Biomedicines 12, 702, https:\/\/doi.org\/10.3390\/biomedicines12030702 (2024).","journal-title":"Biomedicines"},{"key":"5497_CR6","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(20)32115-2","volume":"396","author":"CJ Black","year":"2020","unstructured":"Black, C. J., Drossman, D. A., Talley, N. J., Ruddy, J. & Ford, A. C. Functional gastrointestinal disorders: advances in understanding and management. Lancet 396, 1664\u20131674, https:\/\/doi.org\/10.1016\/S0140-6736(20)32115-2 (2020).","journal-title":"Lancet"},{"key":"5497_CR7","doi-asserted-by":"publisher","unstructured":"DA, D. R. & Tack, J. Rome Foundation clinical diagnostic criteria for disorders of gut-brain interaction. Gastroenterology 162, 675\u2013679, https:\/\/doi.org\/10.1053\/j.gastro.2021.11.019 (2022).","DOI":"10.1053\/j.gastro.2021.11.019"},{"key":"5497_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/jgh3.12528","volume":"5","author":"L Wei","year":"2021","unstructured":"Wei, L., Singh, R., Ro, S. & Ghoshal, U. C. Gut microbiota dysbiosis in functional gastrointestinal disorders: Underpinning the symptoms and pathophysiology. JGH Open 5, 976\u2013987, https:\/\/doi.org\/10.1002\/jgh3.12528 (2021).","journal-title":"JGH Open"},{"key":"5497_CR9","first-page":"539","volume":"15","author":"G Burns","year":"2019","unstructured":"Burns, G. et al. Immune activation in functional gastrointestinal disorders. Gastroenterol. Hepatol. 15, 539\u2013548 (2019).","journal-title":"Gastroenterol. Hepatol."},{"key":"5497_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mehy.2016.11.012","volume":"98","author":"M Ufnal","year":"2017","unstructured":"Ufnal, M. & Pham, K. The gut-blood barrier permeability - a new marker in cardiovascular and metabolic diseases? Med. Hypotheses 98, 35\u201337, https:\/\/doi.org\/10.1016\/j.mehy.2016.11.012 (2017).","journal-title":"Med. Hypotheses"},{"key":"5497_CR11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/jocd.15582","volume":"22","author":"D Rafik","year":"2023","unstructured":"Rafik, D., Younis, I., Atef, R. & Eid, H. Claudin-3 is a novel intestinal integrity marker in patients with alopecia areata: correlation with the disease severity. J. Cosmet. Dermatol 22, 1377\u20131381, https:\/\/doi.org\/10.1111\/jocd.15582 (2023).","journal-title":"J. Cosmet. Dermatol"},{"key":"5497_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3389\/fimmu.2019.01441","volume":"10","author":"L Zhu","year":"2019","unstructured":"Zhu, L. et al. Claudin family participates in the pathogenesis of inflammatory bowel diseases and colitis-associated colorectal cancer. Front Immunol. 10, 1441, https:\/\/doi.org\/10.3389\/fimmu.2019.01441 (2019).","journal-title":"Front Immunol."},{"key":"5497_CR13","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/jdv.15700","volume":"33","author":"M Sikora","year":"2019","unstructured":"Sikora, M. et al. Claudin-3 - a new intestinal integrity marker in patients with psoriasis: association with disease severity. J. Eur. Acad. Dermatol Venereol. 33, 1907\u20131912, https:\/\/doi.org\/10.1111\/jdv.15700 (2019).","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"5497_CR14","doi-asserted-by":"publisher","first-page":"2282789","DOI":"10.1080\/19490976.2023.2282789","volume":"15","author":"R Ahmad","year":"2023","unstructured":"Ahmad, R. et al. Loss of claudin-3 expression increases colitis risk by promoting gut dysbiosis. Gut Microbes 15, 2282789, https:\/\/doi.org\/10.1080\/19490976.2023.2282789 (2023).","journal-title":"Gut Microbes"},{"key":"5497_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17474124.2017.1282820","volume":"11","author":"IJN Koppen","year":"2017","unstructured":"Koppen, I. J. N., Nurko, S., Saps, M., Di Lorenzo, C. & Benninga, M. A. The pediatric Rome IV criteria: what\u2019s new? Expert Rev. Gastroenterol. Hepatol. 11, 193\u2013201, https:\/\/doi.org\/10.1080\/17474124.2017.1282820 (2017).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"5497_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/gidisord6010021","volume":"6","author":"A Vernon-Roberts","year":"2024","unstructured":"Vernon-Roberts, A., Safe, M. & Day, A. S. Editorial: pediatric functional gastrointestinal disorders: challenges in diagnosis and treatment. Gastrointest. Disord. 6, 308\u2013312, https:\/\/doi.org\/10.3390\/gidisord6010021 (2024).","journal-title":"Gastrointest. Disord."},{"key":"5497_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1000-1948(07)60033-1","volume":"22","author":"WM Kong","year":"2007","unstructured":"Kong, W. M., Gong, J., Dong, L., Lu, X. L. & Xu, J. Expression of intestinal mucosa tight junctions claudin proteins and mRNA in patients with irritable bowel syndrome. J. Med. Coll. PLA 22, 153\u2013159, https:\/\/doi.org\/10.1016\/S1000-1948(07)60033-1 (2007).","journal-title":"J. Med. Coll. PLA"},{"key":"5497_CR18","doi-asserted-by":"publisher","first-page":"e13576","DOI":"10.1111\/nmo.13576","volume":"31","author":"M Taki","year":"2019","unstructured":"Taki, M. et al. Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol. Motil. 31, e13576, https:\/\/doi.org\/10.1111\/nmo.13576 (2019).","journal-title":"Neurogastroenterol. Motil."},{"key":"5497_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/gutjnl-2012-303857","volume":"63","author":"H Vanheel","year":"2014","unstructured":"Vanheel, H. et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut 63, 262\u2013271, https:\/\/doi.org\/10.1136\/gutjnl-2012-303857 (2014).","journal-title":"Gut"},{"key":"5497_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/cells12020236","volume":"12","author":"K Awad","year":"2023","unstructured":"Awad, K. et al. Impaired intestinal permeability of tricellular tight junctions in patients with irritable bowel syndrome with mixed bowel habits (IBS-M). Cells 12, 236, https:\/\/doi.org\/10.3390\/cells12020236 (2023).","journal-title":"Cells"},{"key":"5497_CR21","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.14309\/ajg.0000000000000827","volume":"115","author":"B Nojkov","year":"2020","unstructured":"Nojkov, B. et al. Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and \u201cex vivo\u201d mucosa analysis. Am. J. Gastroenterol. 115, 1891\u20131901, https:\/\/doi.org\/10.14309\/ajg.0000000000000827 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"5497_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.26565\/2313-6693-2019-38-07","volume":"38","author":"N Shevchenko","year":"2019","unstructured":"Shevchenko, N. et al. Level of proinflammatory cytokines in children with various clinical forms of functional dyspepsia. J. V. N. Karazin Kharkiv Natl. Univ., Ser. \u201cMed.\u201d 38, 56\u201362, https:\/\/doi.org\/10.26565\/2313-6693-2019-38-07 (2019).","journal-title":"J. V. N. Karazin Kharkiv Natl. Univ., Ser. \u201cMed.\u201d"},{"key":"5497_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/MPG.0b013e3181fd9816","volume":"52","author":"MC Hua","year":"2011","unstructured":"Hua, M. C. et al. Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. J. Pediatr. Gastroenterol. Nutr. 52, 376\u2013381, https:\/\/doi.org\/10.1097\/MPG.0b013e3181fd9816 (2011).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5497_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cyto.2017.05.005","volume":"93","author":"R Choghakhori","year":"2017","unstructured":"Choghakhori, R., Abbasnezhad, A., Hasanvand, A. & Amani, R. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life. Cytokine 93, 34\u201343, https:\/\/doi.org\/10.1016\/j.cyto.2017.05.005 (2017).","journal-title":"Cytokine"},{"key":"5497_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.clinre.2015.12.013","volume":"40","author":"S Seyedmirzaee","year":"2016","unstructured":"Seyedmirzaee, S. et al. Serum immune biomarkers in irritable bowel syndrome. Clin. Res. Hepatol. Gastroenterol. 40, 631\u2013637, https:\/\/doi.org\/10.1016\/j.clinre.2015.12.013 (2016).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"5497_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7869\/tg.2012.66","volume":"33","author":"SV Rana","year":"2012","unstructured":"Rana, S. V. et al. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop. Gastroenterol. 33, 251\u2013256, https:\/\/doi.org\/10.7869\/tg.2012.66 (2012).","journal-title":"Trop. Gastroenterol."},{"key":"5497_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12519-018-0144-8","volume":"14","author":"C C\u0131ral\u0131","year":"2018","unstructured":"C\u0131ral\u0131, C., Ulusoy, E., Kume, T. & Arslan, N. Elevated serum neopterin levels in children with functional constipation: association with systemic proinflammatory cytokines. World J. Pediatr. 14, 448\u2013453, https:\/\/doi.org\/10.1007\/s12519-018-0144-8 (2018).","journal-title":"World J. Pediatr."},{"key":"5497_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.rgmxen.2014.11.006","volume":"80","author":"R V\u00e1zquez-Frias","year":"2015","unstructured":"V\u00e1zquez-Frias, R. et al. Proinflammatory and anti-inflammatory cytokine profile in pediatric patients with irritable bowel syndrome. Rev. de. Gastroenterol.\u00eda de. M\u00e9xico 80, 6\u201312, https:\/\/doi.org\/10.1016\/j.rgmxen.2014.11.006 (2015).","journal-title":"Rev. de. Gastroenterol.\u00eda de. M\u00e9xico"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05497-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:41:22Z","timestamp":1793025682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05497-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":28,"alternative-id":["5497"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05497-0","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study has been approved by the Ethics Committee of the National Research Centre, Egypt (Approval No.: 19\/224) in accordance with the ethical standards of the 1975 Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed written consent was obtained from all guardians after explaining the study objectives and guaranteeing the confidentiality of patient data.","order":3,"name":"Ethics","label":"Informed consents","group":{"name":"EthicsHeading","label":"Ethics"}}]}}